A multicenter retrospective analysis including 100 NSCLC-BM patients treated with upfront ICIs showed a CNS ORR of 27% among evaluable patients and rates of 35.7% in PD-L1-positive and 11.1% in PD-L1-negative tumors [172]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.